Genetic Polymorphisms in CYP2C19 Cause Changes in Plasma Levels and Adverse Reactions to Anlotinib in Chinese Patients With Lung Cancer

Genetic Polymorphisms in CYP2C19 Cause Changes in Plasma Levels and Adverse Reactions to Anlotinib in Chinese Patients With Lung Cancer

Background: Anlotinib is a small molecular multi-targeting tyrosine kinase inhibitor. Growing evidence indicates that treatment efficacy, and toxicity varies considerably between individuals. Therefore, this study aimed to investigate the relationship between cytochrome P450 (CYP450) gene polymorphi...

Full description

Bibliographic Details
Main Authors: Tingfei Tan, Gongwei Han, Ziwei Cheng, Jiemei Jiang, Li Zhang, Zitong Xia, Xinmeng Wang, Quan Xia
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Pharmacology
Subjects:
anlotinib
lung cancer
CYP450 gene polymorphisms
plasma concentration
adverse reactions
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.918219/full

Similar Items

Similar Items